- Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks -
- Favorable safety results observed: AL102 was well tolerated -
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
- Tumor shrinking observed in substantially all patients who were evaluable at 16 weeks -
- Favorable safety results observed: AL102 was well tolerated -
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| AYLA | 0.5036 | +0.0278 | +5.84% |
| Ayala Pharmaceuticals Inc | |||